BioSpace News Archive

Clinical stage drug development company FAScinate Therapeutics, Inc. today announced that its Investigational New Drug (IND) application for Phase 2 trials of its Parkinson’s Disease treatment “KM-819” has been cleared by the United States Food and Drug Administration (FDA).

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference.

Gritstone bio, Inc., a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, announced that the company’s Board of Directors has granted fourteen employees nonqualified stock options to purchase an aggregate of 109,000 shares of its common stock with an exercise price of $10.87, which is equal to the closing price of Gritstone’s common stock on November 16, 2021, the grant date of the awards.

Shoreline Biosciences, Inc. announced that company management will present and conduct one-on-one meetings at the Piper Sandler 33rd Annual Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference:

Exscientia (Nasdaq: EXAI) today announced they will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).

Sesen Bio today announced that Jane Pritchett Henderson, previously a member of Sesen Bio’s Board of Directors and the Chair of the Board’s Audit Committee, has transitioned off the Board of Directors to a CEO Advisor role, effective November 22, 2021.

Aytu BioPharma, Inc. announced that today the United States Patent and Trademark Office (USPTO) has issued a U.S. patent for the Healight ultraviolet-A light-based respiratory catheter.

AbbVie will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021.

Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 75% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in December.